1
|
Thirunavu VM, Mohammad LM, Kandula V, Beestrum M, Lam SK. Vision Outcomes for Pediatric Patients With Optic Pathway Gliomas Associated With Neurofibromatosis Type I: A Systematic Review of the Clinical Evidence. J Pediatr Hematol Oncol 2021; 43:135-143. [PMID: 33480655 DOI: 10.1097/mph.0000000000002060] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/23/2020] [Accepted: 12/08/2020] [Indexed: 01/14/2023]
Abstract
Children with neurofibromatosis type I (NF1) have a higher predisposition for low-grade astrocytomas of the optic pathway, commonly referred to as optic pathway gliomas (OPGs). OPGs can result in visual deterioration. Treatment outcomes in OPG-NF1 management are often reported around tumor stabilization. We sought to compare vision outcomes associated with different OPG treatment strategies to inform about this important functional metric. A meta-analysis exploring the different modalities to treat children with OPG-NF1 was conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines using multiple databases. Of the 113 articles identified in the search, 23 full text articles, representing 564 patients, were included for review. These articles included retrospective, prospective, and randomized controlled studies on observation (n=9), chemotherapy (n=19), radiation therapy (n=6), and surgery (n=7). Of the patients undergoing observation, 87% (60/69) demonstrated stable acuity. In the chemotherapy studies, 27.3% (72/264) demonstrated improved acuity/visual field and/or visual-evoked potential amplitudes, 39.4% (104/264) stable acuity, and 33.3% (88/264) deterioration. Both the radiation and surgical treatments reported worsening acuity at 90.9% (10/11) and 73.3% (11/15), respectively. Causal associations are not known. Indications for and timing of treatment choice warrant larger scale study to provide further understanding.
Collapse
Affiliation(s)
| | - Laila M Mohammad
- Department of Neurological Surgery, Division of Pediatric Neurosurgery
| | - Viswajit Kandula
- Department of Neurological Surgery, Division of Pediatric Neurosurgery
| | - Molly Beestrum
- Galter Health Sciences Library, Northwestern University Feinberg School of Medicine, Chicago, IL
| | - Sandi K Lam
- Department of Neurological Surgery, Division of Pediatric Neurosurgery
| |
Collapse
|
2
|
Abstract
BACKGROUND Radiotherapy has been proposed as a treatment for new vessel growth in people with neovascular age-related macular degeneration (AMD). OBJECTIVES To examine the effects of radiotherapy on neovascular AMD. SEARCH METHODS We searched CENTRAL, MEDLINE, Embase, LILACS and three trials registers and checked references of included studies. We last searched the databases on 4 May 2020. SELECTION CRITERIA: We included all randomised controlled trials in which radiotherapy was compared to another treatment, sham treatment, low dosage irradiation or no treatment in people with choroidal neovascularisation (CNV) secondary to AMD. DATA COLLECTION AND ANALYSIS We used standard procedures expected by Cochrane. We graded the certainty of the evidence using GRADE. We considered the following outcomes at 12 months: best-corrected visual acuity (BCVA) (loss of 3 or more lines, change in visual acuity), contrast sensitivity, new vessel growth, quality of life and adverse effects at any time point. MAIN RESULTS: We included 18 studies (n = 2430 people, 2432 eyes) of radiation therapy with dosages ranging from 7.5 to 24 Gy. These studies mainly took place in Europe and North America but two studies were from Japan and one multicentre study included sites in South America. Three of these studies investigated brachytherapy (plaque and epimacular), the rest were studies of external beam radiotherapy (EBM) including one trial of stereotactic radiotherapy. Four studies compared radiotherapy combined with anti-vascular endothelial growth factor (anti-VEGF) with anti-VEGF alone. Eleven studies gave no radiotherapy treatment to the control group; five studies used sham irradiation; and one study used very low-dose irradiation (1 Gy). One study used a mixture of sham irradiation and no treatment. Fifteen studies were judged to be at high risk of bias in one or more domains. Radiotherapy versus no radiotherapy There may be little or no difference in loss of 3 lines of vision at 12 months in eyes treated with radiotherapy compared with no radiotherapy (risk ratio (RR) 0.82, 95% confidence interval (CI) 0.64 to 1.04, 811 eyes, 8 studies, I2 = 66%, low-certainty evidence). Low-certainty evidence suggests a small benefit in change in visual acuity (mean difference (MD) -0.10 logMAR, 95% CI -0.17 to -0.03; eyes = 883; studies = 10) and average contrast sensitivity at 12 months (MD 0.15 log units, 95% CI 0.05 to 0.25; eyes = 267; studies = 2). Growth of new vessels (largely change in CNV size) was variably reported and It was not possible to produce a summary estimate of this outcome. The studies were small with imprecise estimates and there was no consistent pattern to the study results (very low-certainty evidence). Quality of life was only reported in one study of 199 people; there was no clear difference between treatment and control groups (low-certainty evidence). Low-certainty evidence was available on adverse effects from eight of 14 studies. Seven studies reported on radiation retinopathy and/or neuropathy. Five of these studies reported no radiation-associated adverse effects. One study of 88 eyes reported one case of possible radiation retinopathy. One study of 74 eyes graded retinal abnormalities in some detail and found that 72% of participants who had radiation compared with 71% of participants in the control group had retinal abnormalities resembling radiation retinopathy or choroidopathy. Four studies reported cataract surgery or progression: events were generally few with no consistent evidence of any increased occurrence in the radiation group. One study noted transient disturbance of the precorneal tear film but there was no evidence from the other two studies that reported dry eye of any increased risk with radiation therapy. None of the participants received anti-VEGF injections. Radiotherapy combined with anti-VEGF versus anti-VEGF alone People receiving radiotherapy/anti-VEGF were probably more likely to lose 3 or more lines of BCVA at 12 months compared with anti-VEGF alone (RR 2.11, 95% CI 1.40 to 3.17, 1050 eyes, 3 studies, moderate-certainty). Most of the data for this outcome come from two studies of epimacular brachytherapy (114 events) compared with 20 events from the one trial of EBM. Data on change in BCVA were heterogenous (I2 = 82%). Individual study results ranged from a small difference of -0.03 logMAR in favour of radiotherapy/anti-VEGF to a difference of 0.13 logMAR in favour of anti-VEGF alone (low-certainty evidence). The effect differed depending on how the radiotherapy was delivered (test for interaction P = 0.0007). Epimacular brachytherapy was associated with worse visual outcomes (MD 0.10 logMAR, 95% CI 0.05 to 0.15, 820 eyes, 2 studies) compared with EBM (MD -0.03 logMAR, 95% CI -0.09 to 0.03, 252 eyes, 2 studies). None of the included studies reported contrast sensitivity or quality of life. Growth of new vessels (largely change in CNV size) was variably reported in three studies (803 eyes). It was not possible to produce a summary estimate and there was no consistent pattern to the study results (very low-certainty evidence). For adverse outcomes, variable results were reported in the four studies. In three studies reports of adverse events were low and no radiation-associated adverse events were reported. In one study of epimacular brachytherapy there was a higher proportion of ocular adverse events (54%) compared to the anti-VEGF alone (18%). The majority of these adverse events were cataract. Overall 5% of the treatment group had radiation device-related adverse events (17 cases); 10 of these cases were radiation retinopathy. There were differences in average number of injections given between the four studies (1072 eyes). In three of the four studies, the anti-VEGF alone group on average received more injections (moderate-certainty evidence). AUTHORS' CONCLUSIONS The evidence is uncertain regarding the use of radiotherapy for neovascular AMD. Most studies took place before the routine use of anti-VEGF, and before the development of modern radiotherapy techniques such as stereotactic radiotherapy. Visual outcomes with epimacular brachytherapy are likely to be worse, with an increased risk of adverse events, probably related to vitrectomy. The role of stereotactic radiotherapy combined with anti-VEGF is currently uncertain. Further research on radiotherapy for neovascular AMD may not be justified until current ongoing studies have reported their results.
Collapse
Affiliation(s)
- Jennifer R Evans
- Cochrane Eyes and Vision, ICEH, London School of Hygiene & Tropical Medicine, London, UK
| | | | | | | |
Collapse
|
3
|
Dehoog E, Van Dine R, Fitzgerald-Dehoog L, Schwiegerling J. Relating wavefront error to visual acuity in pre- and post-LASIK eyes: a comparison of methods. J Opt Soc Am A Opt Image Sci Vis 2020; 37:192-198. [PMID: 32118897 DOI: 10.1364/josaa.37.000192] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/30/2019] [Accepted: 12/02/2019] [Indexed: 06/10/2023]
Abstract
Contrast threshold and visual Strehl ratio methods are used to predict visual acuity from wavefront error for a sample population of pre- and post-LASIK patients. Relative error (in logMAR) between predicted and measured visual acuity values are computed for each method and compared using paired t-tests. Differences in aberration data between pre- and post-LASIK eyes are then evaluated. The visual acuity prediction using visual Strehl proved to be more accurate for pre-LASIK patients than contrast threshold. However, both methods are comparable for post-LASIK patients.
Collapse
|
4
|
Pagliara MM, Tagliaferri L, Lenkowicz J, Azario L, Giattini D, Fionda B, Sammarco MG, Lancellotta V, Gambacorta MA, Blasi MA. AVATAR: Analysis for Visual Acuity Prediction After Eye Interventional Radiotherapy. In Vivo 2020; 34:381-387. [PMID: 31882502 PMCID: PMC6984081 DOI: 10.21873/invivo.11784] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2019] [Revised: 10/02/2019] [Accepted: 10/07/2019] [Indexed: 12/26/2022]
Abstract
AIM The aim of this study was to detect clinical factors predictive of loss of visual acuity after treatment in order to develop a predictive model to help identify patients at risk of visual loss. PATIENTS AND METHODS This was a retrospective review of patients who underwent interventional radiotherapy (brachytherapy) with 106Ru plaque for primary uveal melanoma. A predictive nomogram for visual acuity loss at 3 years from treatment was developed. RESULTS A total of 152 patients were selected for the study. The actuarial probability of conservation of 20/40 vision or better was 0.74 at 1 year, 0.59 at 3 years, and 0.54 at 5 years after treatment. Factors positively correlated with loss of visual acuity included: age at start of treatment (p=0.004) and longitudinal basal diameter (p=0.057), while distance of the posterior margin of the tumor from the foveola was inversely correlated (p=0.0007). CONCLUSION We identified risk factors affecting visual function and developed a predictive model and decision support tool (AVATAR nomogram).
Collapse
Affiliation(s)
- Monica Maria Pagliara
- U.O.C. Oncologia Oculare, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
| | - Luca Tagliaferri
- U.O.C. Radioterapia Oncologica, Dipartimento di Diagnostica per immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
| | - Jacopo Lenkowicz
- U.O.C. Radioterapia Oncologica, Dipartimento di Diagnostica per immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
- Istituto di Radiologia, Università Cattolica del Sacro Cuore, Rome, Italy
| | - Luigi Azario
- U.O.C. Fisica Sanitaria, Dipartimento di Diagnostica per immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
- Istituto di Fisica, Università Cattolica del Sacro Cuore, Rome, Italy
| | - Dario Giattini
- Ophthalmology Clinic, Department of Medicine and Aging Science, G. d'Annunzio University of Chieti-Pescara, Chieti, Italy
| | - Bruno Fionda
- U.O.C. Radioterapia Oncologica, Dipartimento di Diagnostica per immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
| | - Maria Grazia Sammarco
- U.O.C. Oncologia Oculare, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
| | - Valentina Lancellotta
- U.O.C. Radioterapia Oncologica, Dipartimento di Diagnostica per immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
| | - Maria Antonietta Gambacorta
- U.O.C. Radioterapia Oncologica, Dipartimento di Diagnostica per immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
- Istituto di Radiologia, Università Cattolica del Sacro Cuore, Rome, Italy
| | - Maria Antonietta Blasi
- U.O.C. Oncologia Oculare, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
- Istituto di Oftalmologia, Università Cattolica del Sacro Cuore, Rome, Italy
| |
Collapse
|
5
|
Zhou L, Chong V, Lai K, Huang C, Xu F, Gong Y, Youlidaxi M, Li T, Lu L, Jin C. A pilot prospective study of 577-nm yellow subthreshold micropulse laser treatment with two different power settings for acute central serous chorioretinopathy. Lasers Med Sci 2019; 34:1345-1351. [PMID: 30710172 DOI: 10.1007/s10103-019-02721-8] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2017] [Accepted: 01/14/2019] [Indexed: 02/02/2023]
Abstract
To compare the efficacy of 50% threshold power with 25% threshold power of 577-nm subthreshold micropulse laser (SMPL) for acute central serous chorioretinopathy (CSC). Prospective, interventional, non-randomized, comparative case series. A total of 54 patients (54 eyes) with acute CSC were enrolled. Twenty-four eyes received 25% threshold power and 30 eyes received 50% threshold power of 577-nm SMPL. Best-corrected visual acuity (BCVA), central macular thickness (CMT), and complete absorption of subretinal fluid (SRF) were evaluated at 1 month and 3 months. The complete absorption rate of SRF in the 50% power group was significantly greater than that in the 25% power group at 1 month (70.0% vs 25.0%, p < 0.001) and at 3 months (83.3% vs 54.2%, p < 0.001). Mean BCVA improved from 0.34 ± 0.20 LogMAR to 0.02 ± 0.13 LogMAR in the 50% power group and from 0.27 ± 0.15 LogMAR to 0.14 ± 0.21 LogMAR in the 25% power group with a significant difference between the two groups after 3 months (p = 0.027). In the 50% power group, the CMT decreased from 491.6 ± 154.8 μm at baseline to 231.3 ± 92.3 μm at 1 month and 228.2 ± 88.1 μm at 3 months, and in the 25% power group, the CMT decreased from 444.9 ± 164.1 to 306.8 ± 102.6 μm at 1 month and 254.5 ± 101.7 μm at 3 months. There was statistical difference of CMT at 1 month (p = 0.009) but no significant difference at 3 months between the two groups (p = 0.232). SMPL with 50% threshold power may be more effective than 25% threshold power for acute CSC.
Collapse
Affiliation(s)
- Lijun Zhou
- State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou City, China
| | | | - Kunbei Lai
- State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou City, China
| | - Chuangxin Huang
- State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou City, China
| | - Fabao Xu
- State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou City, China
| | - Yajun Gong
- State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou City, China
| | | | - Tao Li
- State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou City, China
| | - Lin Lu
- State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou City, China
| | - Chenjin Jin
- State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou City, China.
| |
Collapse
|
6
|
Stahl MH, Kumar A, Lambert R, Stroud M, Macleod D, Bastawrous A, Peto T, Burton MJ. Antarctica eye study: a prospective study of the effects of overwintering on ocular parameters and visual function. BMC Ophthalmol 2018; 18:149. [PMID: 29940901 PMCID: PMC6019514 DOI: 10.1186/s12886-018-0816-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2018] [Accepted: 06/08/2018] [Indexed: 12/05/2022] Open
Abstract
BACKGROUND In 2013 five polar explorers attempted to complete the first Trans-Antarctic Winter Traverse (TAWT). This study presents the ophthalmological findings for this group, who overwintered in Antarctica as part of the White Mars Human Science Protocol. Antarctic crews are exposed to extreme cold, chronic hypoxia and altered day-night cycles. Previous studies of Antarctic explorers have focused on the prolonged effect of ultraviolet radiation including the development of ultraviolet keratitis and accelerated cataract formation. This is the first study of its kind to investigate the effect of overwintering in Antarctica on the human eye. METHODS Pre and post-expedition clinical observations were made including visual acuity, contrast sensitivity, colour vision, auto-refraction, subjective refraction, retinal examination, retinal autofluoresence and retinal thickness, which were graded for comparison. During the expedition additional observations were made on a monthly basis including LogMAR visual acuity, autorefraction and intraocular pressure. RESULTS No significant differences between pre and post-expedition observations were found, including visual acuity, contrast sensitivity, colour vision, refraction, visual fields, intraocular pressure and retinal examination. There was a small but statistically significant decrease in retinal thickness across all regions of the retina, except for the macular and fovea, in all explorers. Intra-expedition observations remained within normal limits. CONCLUSION Reassuringly, the human eye remains largely unchanged by exposure to the extreme conditions encountered during the Antarctic winter, however, further research is needed to investigate changes in retinal thickness. This may have implications for scientists who spend prolonged periods of time in the polar regions, as well as those who have prolonged exposure to the extreme cold or chronic hypoxia in other settings.
Collapse
Affiliation(s)
- Matthew H. Stahl
- University College London, London, UK
- Department of Medicine, Wexham Park Hospital, Wexham, Slough, SL2 4HL UK
| | - Alexander Kumar
- King’s College London, London, UK
- University of Fribourg, Fribourg, Switzerland
| | - Robert Lambert
- Department of Trauma & Orthopaedic Surgery, Royal Infirmary of Edinburgh, Edinburgh, Scotland
| | - Michael Stroud
- University of Southampton Medical School, Southampton, UK
| | - David Macleod
- Clinical Research Department, International Centre for Eye Health, London School of Hygiene & Tropical Medicine, London, UK
| | - Andrew Bastawrous
- Clinical Research Department, International Centre for Eye Health, London School of Hygiene & Tropical Medicine, London, UK
| | - Tunde Peto
- Moorfields Eye Hospital NHS Foundation Trust, London, UK
- Queens University Belfast, Belfast, UK
| | - Matthew J. Burton
- Clinical Research Department, International Centre for Eye Health, London School of Hygiene & Tropical Medicine, London, UK
- Moorfields Eye Hospital NHS Foundation Trust, London, UK
| |
Collapse
|
7
|
Tarmann L, Wackernagel W, Ivastinovic D, Schneider M, Winkler P, Langmann G. Tumor parameters predict the risk of side effects after ruthenium-106 plaque brachytherapy of uveal melanomas. PLoS One 2017; 12:e0183833. [PMID: 28859118 PMCID: PMC5578662 DOI: 10.1371/journal.pone.0183833] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2017] [Accepted: 08/12/2017] [Indexed: 11/18/2022] Open
Abstract
BACKGROUND To report on radiation-related side effects and complications after ruthenium-106 plaque brachytherapy of uveal melanomas. METHODS Medical records of 143 eyes with uveal melanoma, treated by ruthenium-106 brachytherapy between 1997 and 2012 at a single center, were analyzed. We evaluated the occurrence of radiation-related side effects on the anterior and posterior segment of the eye. The influence of patient, tumor and treatment parameters on outcome was analyzed by multivariate time to event analysis considering competing risks. RESULTS The median overall follow-up was 37.9 months. After treatment, the estimated risk at 12, 24 and 48 months for developing anterior segment complications was 25.3%, 37.5% and 50.3% for cataract formation and 5.4%, 6.4% and 8.1% for secondary glaucoma, respectively. The estimated risk for the occurrence of posterior segment complications 12, 24 and 48 months after treatment was 3.1%, 6.7% and 18.3% for radiation retinopathy, 18.3%, 27.1% and 42.6% for radiation maculopathy and 16.5%, 21.0% and 32.8% for radiation neuropathy, respectively. The risk of an increase in retinal detachment after treatment was 14.7%, 14.7% and 17.4% at 12, 24 and 48 months, respectively. The risk of vitreous hemorrhage occurring after treatment was 6.2%, 8.1% and 12.7%, and the risk of tumor vasculopathy was 15.4%, 17.4% and 19.0%. Scleral necrosis was observed in one patient. CONCLUSION Radiation-related side effects and complications are common among patients treated with ruthenium brachytherapy for uveal melanoma. However, the risk for those largely depends on individual tumor parameters. Before treatment, patients should be informed of their specific risks to develop various side effects. Patient information before treatment should cover not only general information about the treatment and possible complications and side effects but should also give details on the specific risks of the patient in her individual situation. This also includes elucidating the patient's individual resources and expectations and her willingness for long-term regular follow-up examinations and secondary adjunct treatments.
Collapse
Affiliation(s)
- Lisa Tarmann
- Department of Ophthalmology, Medical University Graz, Graz, Austria
| | - Werner Wackernagel
- Department of Ophthalmology, Medical University Graz, Graz, Austria
- * E-mail:
| | | | - Mona Schneider
- Department of Ophthalmology, Medical University Graz, Graz, Austria
| | - Peter Winkler
- Department of Therapeutic Radiology and Oncology, Medical University Graz, Graz, Austria
| | - Gerald Langmann
- Department of Ophthalmology, Medical University Graz, Graz, Austria
| |
Collapse
|
8
|
Abstract
BACKGROUND Radiation maculopathy is a phenomenon that occurs after radiation exposure. The rapid onset of unilateral macular atrophy without peripheral retinopathy after radiation has rarely been described. METHODS A case report and literature review. RESULTS We report a case of stage 4 non-small cell lung cancer under targeted therapy using Gefitinib who presented with severely impaired visual acuity related to rapid onset of unilateral macular atrophy and diminished photoreceptor inner segment/outer segment (IS/OS) junction 1 month after whole-brain radiation therapy. The fundus fluorescein angiography revealed an enlarged diamond-shaped clear-cut foveal avascular zone in the macula without peripheral retinal vascular changes that differed from typical radiation retinopathy. We confirmed the diagnosis by evaluating the total radiation dosage and by excluding target therapy-induced maculopathy based on a review of the medical literature. CONCLUSION Current therapeutic interventions for macular atrophy after radiation therapy remain a challenge. Vasodilators or antiplatelet medication may be beneficial; however, long-term follow-up is needed. Further studies are required to support the use of early aggressive therapy for the prevention of radiation retinopathy.
Collapse
Affiliation(s)
| | | | | | - Ke-Hung Chien
- Department of Ophthalmology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
- Correspondence: Ke-Hung Chien, Department of Ophthalmology, Tri-Service General Hospital, Neihu Dist, Taipei City, Taiwan (R.O.C.) (e-mail: )
| |
Collapse
|
9
|
Romanowska-Dixon B, Markiewicz A, Sas-Korczyńska B, Medoń D, Walasek T. [Evaluation of intraocular proton beam irradiation complications after choroidal melanoma treatment]. Klin Oczna 2016; 118:289-292. [PMID: 29911361] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
PURPOSE The aim of the research was to evaluate of intraocular complications after proton beam therapy of choroidal melanomas MATERIAL AND METHODS A total 105 patients (48 female and 57 male) from Department of Ophthalmology and Ocular Oncology of University Hospital in Cracow, who received proton beam radiation due to choroidal melanoma were enrolled. The mean age was 52.3 years (51.8 y. in females, 52.6 y. in males). Total irradiation dose was 60 cGy and it was applied in 4 fractions per 15 cGy (on 4 consecutive days). We evaluated the incidence of complications classifying patients by age, tumor location, tumor thickness, longitudinal and transversal basal diameter and follow-up period, which ranged between 5 and 57 months. RESULTS Complications of intraocular irradiation were observed in 33 out of 105 treated patients. Retinopathy occurred in 18 cases, including 4 patients with macular edema. Neuropathy was confirmed in 8 patients, secondary glaucoma in 6 cases; we noted 9 cases of initial or progress existing cataract, 4 cases of dry eye syndrome and 1 patient with central retinal vein occlusion. A statistically significant positive correlation was demonstrated between the length of the follow-up period and the incidence of complications, which were more common and more severe with the longer follow-up period. There was no statistically significant correlation between the incidence of complications and patient’s age, tumor location, tumor thickness as well as longitudinal and transversal basal diameter. CONCLUSION All forms of radiation therapy used in intraocular tumors are associated with some risk of complications; proton beam radiotherapy is not free of that risk, either.
Collapse
|
10
|
Turkoglu EB, Celık E, Aksoy N, Bursalı O, Ucak T, Alagoz G. Changes in vision related quality of life in patients with diabetic macular edema: ranibizumab or laser treatment? J Diabetes Complications 2015; 29:540-3. [PMID: 25817172 DOI: 10.1016/j.jdiacomp.2015.03.009] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/22/2015] [Revised: 02/16/2015] [Accepted: 03/15/2015] [Indexed: 11/21/2022]
Abstract
PURPOSE To compare the changes in vision related quality of life (VR-QoL) in patients with diabetic macular edema (DME) undergoing intravitreal ranibizumab (IVR) injection or focal/grid laser. MATERIAL AND METHODS In this prospective study, 70 patients with clinically significant macular edema (CSME) were randomized to undergo IVR injection (n=35) and focal/grid laser (n=35). If necessary, the laser or ranibizumab injections were repeated. Distance and near visual acuities, central retinal thickness (CRT) and The 25-item Visual Function Questionnaire (VFQ-25) were used to measure the effectiveness of treatments and VR-QoL before and after 6 months following IVR or laser treatment. RESULTS The demographic and clinical findings before the treatments were similar in both main groups. The improvements in distance and near visual acuities were higher in IVR group than the laser group (p<0.01). The reduction in CRT in IVR group was higher than that in laser treatment group (p<0.01). In both groups, the VFQ-25 composite score tended to improve from baseline to 6 months. And at 6th month, the changes in composite score were significantly higher in IVR group than in laser group (p<0.05). The improvements in overall composite scores were 6.3 points for the IVR group compared with 3.0 points in the laser group. Patients treated with IVR and laser had large improvements in composite scores, general vision, near and distance visual acuities in VFQ-25 at 6 months, in comparison with baseline scores, and also mental health subscale in IVR group. CONCLUSION Our study revealed that IVR improved not only visual acuity or CRT, but also vision related quality of life more than laser treatment in DME. And these patient-reported outcomes may play an important role in the treatment choice in DME for clinicians.
Collapse
Affiliation(s)
| | - Erkan Celık
- Sakarya University Medical Education and Research Hospital, Sakarya,Turkey.
| | - Nilgun Aksoy
- Sakarya University Medical Education and Research Hospital, Sakarya,Turkey.
| | - Ozlem Bursalı
- Sakarya University Medical Education and Research Hospital, Sakarya,Turkey.
| | - Turgay Ucak
- Sakarya University Medical Education and Research Hospital, Sakarya,Turkey.
| | - Gursoy Alagoz
- Sakarya University Medical Education and Research Hospital, Sakarya,Turkey.
| |
Collapse
|
11
|
Li Q, Zhang X. [The Influence of risk factors on visual performance in of phototoxic maculopathy in occupational welders]. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi 2014; 32:759-761. [PMID: 25533367] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
OBJECTIVE To investigate the Influence of risk factors that cause the phototoxic maculopathy by welding arc in occupational welders. METHODS We examined randomly a group of 86 male occupational welders 172 eyes from some local metal manufacturing enterprise from August 2010 to December 2013. The ophthalmologic examination which the participants underwent thorough including the best visual acuity, fundus examination by the supplementary lens, fundus photography, and the high definition optical coherence tomography (OCT) scan. All participants of this study underwent thorough the medicine examined by a specialist of occupational who prior to the OCT. All the subjects were divided into groups according to age, protection degrees , length of service, operating time . The incidences of phototoxic maculopathy were compared within groups. The subjects was divided randomly into the lutein group and the placebo group. The examination including the best visual acuity, serum lutein concentrations, macular pigmentoptical density (MPOD), Contrast and glare Sensitivity. RESULTS (1) The total incidence of phototoxic maculopathy is 32.0%. (2) The incidences of phototoxic maculopathy in the strict protection group, the randomed protective group and the nonprofessional protection group were respectively 21.4%, 36.7%, 53.6%. The incidence in the strict protection group was lower than the other two groups, the incidence was the highest in the nonprofessional protection group, and the difference was statistically significant. (3) The longer length of service, and operating time , the more incidence of phototoxic maculopathy develop. (4) The lutein group prior to the placebo group at the best visual acuity, serum lutein concentrations, macular pigmentoptical density (MPOD), Contrast and glare Sensitivity. CONCLUSION The risk factors of phototoxic maculopathy in male occupational welders are the length of service, operating time, protection degrees and the lutein assistantly. The incidence of phototoxic maculopathy occurs regardless of age.
Collapse
Affiliation(s)
- Qingtao Li
- Minda Hospital of Hubei Nationalities Institute, Enshi 445000, China
| | - Xinfang Zhang
- Minda Hospital of Hubei Nationalities Institute, Enshi 445000, China
| |
Collapse
|
12
|
Cain MD, Vo BQ, Kolesnikov AV, Kefalov VJ, Culican SM, Kerschensteiner D, Blumer KJ. An allosteric regulator of R7-RGS proteins influences light-evoked activity and glutamatergic waves in the inner retina. PLoS One 2013; 8:e82276. [PMID: 24349243 PMCID: PMC3857278 DOI: 10.1371/journal.pone.0082276] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2013] [Accepted: 10/31/2013] [Indexed: 11/23/2022] Open
Abstract
In the outer retina, G protein-coupled receptor (GPCR) signaling mediates phototransduction and synaptic transmission between photoreceptors and ON bipolar cells. In contrast, the functions of modulatory GPCR signaling networks in the inner retina are less well understood. We addressed this question by determining the consequences of augmenting modulatory Gi/o signaling driven by endogenous transmitters. This was done by analyzing the effects of genetically ablating the R7 RGS-binding protein (R7BP), a membrane-targeting protein and positive allosteric modulator of R7-RGS (regulator of the G protein signaling 7) family that deactivates Gi/oα subunits. We found that R7BP is expressed highly in starburst amacrine cells and retinal ganglion cells (RGCs). As indicated by electroretinography and multielectrode array recordings of adult retina, ablation of R7BP preserved outer retina function, but altered the firing rate and latency of ON RGCs driven by rods and cones but not rods alone. In developing retina, R7BP ablation increased the burst duration of glutamatergic waves whereas cholinergic waves were unaffected. This effect on glutamatergic waves did not result in impaired segregation of RGC projections to eye-specific domains of the dorsal lateral geniculate nucleus. R7BP knockout mice exhibited normal spatial contrast sensitivity and visual acuity as assessed by optomotor reflexes. Taken together these findings indicate that R7BP-dependent regulation of R7-RGS proteins shapes specific aspects of light-evoked and spontaneous activity of RGCs in mature and developing retina.
Collapse
Affiliation(s)
- Matthew D. Cain
- Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri, United States of America
| | - Bradly Q. Vo
- Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, Missouri, United States of America
| | - Alexander V. Kolesnikov
- Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, Missouri, United States of America
| | - Vladimir J. Kefalov
- Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, Missouri, United States of America
| | - Susan M. Culican
- Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, Missouri, United States of America
| | - Daniel Kerschensteiner
- Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, Missouri, United States of America
| | - Kendall J. Blumer
- Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri, United States of America
- * E-mail:
| |
Collapse
|
13
|
Yang B, Lin Y, Sun Y. Transient effects of harsh luminous conditions on the visual performance of aviators in a civil aircraft cockpit. Appl Ergon 2013; 44:185-191. [PMID: 22858009 DOI: 10.1016/j.apergo.2012.07.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/04/2011] [Revised: 04/20/2012] [Accepted: 07/04/2012] [Indexed: 06/01/2023]
Abstract
The aim of this work was to examine how harsh luminous conditions in a cockpit, such as lightning in a thunderstorm or direct sunlight immediately after an aircraft passes through clouds, may affect the visual performance of pilots, and how to improve it. Such lighting conditions can result in the temporary visual impairment of aviators, which may greatly increase the risk of accidents. Tests were carried out in a full-scale simulator cockpit in which two kinds of dynamic lighting scenes, namely pulse changed and step changed lighting, were used to represent harsh luminous conditions. Visual acuity (VA), reaction time (RT) and identification accuracy (IA) were recorded as dependent variables. Data analysis results indicate that standardized VA values decreased significantly in both pulsing and step conditions in comparison with the dark condition. Standardized RT values increased significantly in the step condition; on the contrary, less reaction time was observed in the pulsing condition. Such effects could be reduced by an ambient illumination provided by a fluorescent lamp in both conditions. The results are to be used as a principle for optimizing lighting design with a thunderstorm light.
Collapse
Affiliation(s)
- Biao Yang
- Engineering Research Center of Advanced Lighting Technology, Ministry of Education, Fudan University, Shanghai 200433, China
| | | | | |
Collapse
|
14
|
Perri P, Fiorica F, D'Angelo S, Lamberti G, Parmeggiani F, Martini A, Carpenteri F, Colosimo C, Micucci M, Perazzini L, De Gugliemo E, Berretta M, Sebastiani A, Cartei F. Ruthenium-106 eye plaque brachytherapy in the conservative treatment of uveal melanoma: a mono-institutional experience. Eur Rev Med Pharmacol Sci 2012; 16:1919-1924. [PMID: 23242717] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
BACKGROUND Traditional treatment for uveal melanoma is the enucleation of the eye with outcomes cosmetically unacceptable and loss of useful vision. Plaque brachytherapy, compared to enucleation, had the advantage to preserve the eye with outcomes cosmetically acceptable and preservation of vision. PATIENTS AND METHODS From July 1990 to December 2009 one hundred forty-two (142) patients (51 males and 91 females) with small to medium uveal melanoma were treated with 106Ru plaque brachytherapy. The patients underwent a complete staging before brachytherapy with indirect ophthalmoscopy and ultrasounds. Mean tumour thickness was 3.26 mm (1.6-6 mm). The dose scheduled was 80-100 Gy to the apex with a maximum dose of 800 Gy to the sclera. RESULTS One hundred forty-two have been treated, nine patients had lost the follow-up and drop out; 133 patients were assessed. Mean follow-up was 7.7 years (6 months-18 years). The overall survival at 5, 10 and 15 years was 92%, 85% and 78% respectively. Cancer fee survival was 95%, 90% and 83%, respectively at 5, 10 and 15 year. Radiation-induced toxicity was represented in 47 patients with a 5 year actuarial survival rate free from complications of 54%. CONCLUSIONS 106Ru plaque brachytherapy is a valid approach for treatment of uveal melanoma. This technique is efficacy and safe, with a low toxicity profile.
Collapse
Affiliation(s)
- P Perri
- Department of Ophthalmology, University Hospital Ferrara, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Chan MD, Melhus CS, Mignano JE, Do-Dai D, Duker JS, Yao KC. Analysis of visual toxicity after gamma knife radiosurgery for treatment of choroidal melanoma: identification of multiple targets and mechanisms of toxicity. Am J Clin Oncol 2011; 34:517-523. [PMID: 22039604] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
OBJECTIVES Identification of the targets of radiation damage after radiosurgical treatment of ocular melanoma will potentially allow for sparing of vision with improved treatment planning. MATERIALS AND METHODS Six patients with ocular melanoma, who had useful vision before therapy, were treated with gamma knife stereotactic radiosurgery with curative intent. Dosimetric analysis of functional targets of radiation damage including the fovea, optic nerve, lens, and iris was carried out. Serial testing of visual acuity and fundoscopic examination were carried out after treatment. RESULTS Visual sparing was achieved in 3 of 6 patients at last followup with a median follow-up of 2 years. The causes of loss of vision in those patients who lost useful vision were retinal detachment, neovascular glaucoma, and optic neuropathy. CONCLUSIONS Preradiosurgical size and location are likely predictors of posttreatment visual outcomes.
Collapse
Affiliation(s)
- Michael D Chan
- Department of Radiation Oncology, Tufts Medical Center, Boston, MA, USA
| | | | | | | | | | | |
Collapse
|
16
|
Ballian N, Androulakis II, Chatzistefanou K, Samara C, Tsiveriotis K, Kaltsas GA. Optic neuropathy following radiotherapy for Cushing's disease: case report and literature review. Hormones (Athens) 2010; 9:269-73. [PMID: 20688625 DOI: 10.1007/bf03401278] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Radiation-induced optic neuropathy is a rare adverse effect of radiotherapy applied for the treatment of pituitary adenomas. We report a patient with a recurrent adrenocorticotrophin secreting pituitary adenoma who received external beam irradiation after failing surgical and medical therapy. Sixteen months after radiotherapy, the patient was presented with declining visual acuity, and radiation-induced optic neuropathy was diagnosed. Despite treatment with glucocorticoids and hyperbaric oxygen, her vision did not improve. The pathophysiology, prevention and treatment of radiation-induced optic neuropathy, including the efficacy of hyperbaric oxygen therapy are reviewed.
Collapse
|
17
|
Abstract
We construct a light-guiding model of the retina outside the fovea, in which an array of glial (Muller) cells permeates the depth of the retina down to the photoreceptors. Based on measured refractive indices, we propagate light to obtain a significant increase of the intensity at the photoreceptors. For pupils up to 6 mm width, the coupling between neighboring cells is only a few percent. Low cross talk over the whole visible spectrum also explains the insensitivity to chromatic aberrations of the eye. The retina is revealed as an optimal structure designed for improving the sharpness of images.
Collapse
Affiliation(s)
- A M Labin
- Physics Department, Technion-Israel Institute of Technology, Haifa 32000, Israel
| | | |
Collapse
|
18
|
Isager P, Ehlers N, Urbak SF, Overgaard J. Visual outcome, local tumour control, and eye preservation after 106Ru/Rh brachytherapy for choroidal melanoma. Acta Oncol 2009; 45:285-93. [PMID: 16644571 DOI: 10.1080/02841860500468950] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
To study the visual outcome, local tumour control, and eye preservation 5 years after ruthenium/rhodium 106 brachytherapy for choroidal melanoma. The study included 55 consecutive patients treated by 106Ru/Rh brachytherapy for a choroidal melanoma during the period 1988-2000 and followed through 2004. The 5-year probability for not losing at least 5 Snellen lines was 59% (n = 45), for retaining a visual acuity of 0.33 or better was 28% (n = 34), and for retaining better than 0.1 was 40% (n = 45). The 5-year probability for no local recurrence was 73% and for eye preservation 72% (n = 55). 106Ru/Rh brachytherapy for choroidal melanoma resulted in a clinically significant vision loss, no local recurrence, and eye preservation in most patients after 5 years. 106Ru/Rh brachytherapy can be regarded as a good treatment option for small and medium-sized tumours but not for large tumours.
Collapse
Affiliation(s)
- Peter Isager
- Department of Ophthalmology, Arhus University Hospital, Denmark.
| | | | | | | |
Collapse
|
19
|
|
20
|
Carlsson L, Knave B, Lennerstrand G, Wibom R. Glare from outdoor high mast lighting: effects on visual acuity and contrast sensitivity in comparative studies of different floodlighting systems. Acta Ophthalmol Suppl 2009; 161:84-93. [PMID: 6328857 DOI: 10.1111/j.1755-3768.1984.tb06787.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
Glare effects on visual acuity and contrast sensitivity were studied at outdoor timber terminal work with conventional far-reaching floodlighting and with a new type of oblique floodlighting with an asymmetrical light distribution. The binocular work visual acuity of 19 volunteers was measured at 40, 55 and 80 per cent contrast and the contrast sensitivity of 14 volunteers at spatial frequencies of 0.5, 1, 2, 4, 8 and 16 cycles/degree. With the light source 15 degrees from the centre of the visual fields the visual acuity as well as the contrast sensitivity was consistently lower with the conventional type than the new type of floodlight . The results thus indicate that not only the vision of details is impaired by glare but also the contrast perception of sparse patterns. In standardized rating scales the timber terminal workers scored the difference in glare between the two floodlight systems as "great"--"very great".
Collapse
|
21
|
de Alba Campomanes AG, Larson DA, Horton JC. Immediate shrinkage of optociliary shunt vessels after fractionated external beam radiation for meningioma of the optic nerve sheath. AJNR Am J Neuroradiol 2008; 29:1360-2. [PMID: 18403557 DOI: 10.3174/ajnr.a1063] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
Fractionated stereotactic radiation has become the standard treatment of meningioma of the optic nerve sheath. The mechanism responsible for improvement in visual function is unclear, because neuroimaging after treatment usually shows no discernable change in tumor appearance. We report immediate regression of optociliary shunt vessels in a patient after radiation treatment of an optic nerve sheath meningioma. This observation indicates that radiation treatment can cause rapid reduction of optic nerve compression, even without appreciable reduction in the size of the meningioma.
Collapse
Affiliation(s)
- A G de Alba Campomanes
- Department of Ophthalmology, University of California, San Francisco, CA 94143-0730, USA
| | | | | |
Collapse
|
22
|
Puchalska-Niedbał L, Sylwestrzak Z, Jarema A. [Radiotherapy of age-related macular degeneration. Case reports]. Klin Oczna 2008; 110:82-87. [PMID: 18669092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
The radiotherapy is worth to remember in the most progression causes of AMD, when there is no possibility for application the modern methods of the treatment. We present cause of patient with bilateral advanced changes and low visual acuity in course AMD, who had applied rtg therapy and laser fotocoagulation. The right eye was radiated with foton beam energy 10 MeV using linear accelerator. Dosage of 9 Gy was delivered in 3 fractions through 5 days. In right eye we observed increase of visual acuity from 2/50 before treatment to 3/50 after 12 months, and 0.1 after the 48 months of radiation. The visual acuity in the left eye decreased from 0.2 to 2/50 after the 48 months. The improvement of acuity vision after rtg therapy allowed the patient self-dependence life.
Collapse
|
23
|
Abstract
PURPOSE To study the incidence, clinical findings, and tumour characteristics of posterior uveal melanoma in Western Norway, and to report the results of a consistent treatment strategy (I-125 brachytherapy or primary enucleation) over a 13-year period. METHODS The clinical records of all patients with posterior uveal melanoma referred between January 1993 and December 2005 were reviewed. Clinical data, radiation parameters, visual outcome, and mortality were analysed in a dedicated database. RESULTS The study included 111 consecutive patients. The annual age-adjusted incidence (per million population) of posterior uveal melanoma was 8.5 for women and 8.9 for men. Fifty-six patients underwent I-125 brachytherapy, 52 were enucleated, and three received no treatment. The median follow-up time was 36 months (mean, 52 months; range, 2 months to 13 years). In the brachytherapy group, two eyes were enucleated owing to tumour recurrence and two because of neovascular glaucoma. A visual acuity of 0.1 or better, present in 87% of the patients before brachytherapy, was retained in 40% after a median follow-up of 61 months. After brachytherapy, the 5- and 10-year melanoma-specific mortality rates were 13.4 and 23.8%, respectively. The corresponding mortality rates for patients treated with primary enucleation were 49.5 and 49.5%. CONCLUSION After brachytherapy, many patients lost useful vision due to radiation-induced complications. The probability of retaining the eye was high and only two patients experienced recurrent tumour growth. The mortality rates compare well with published series, and the differences in tumour size explain the difference in mortality between the two treatment groups.
Collapse
Affiliation(s)
- J Krohn
- Department of Ophthalmology, Haukeland University Hospital, Bergen, Norway.
| | | | | | | | | |
Collapse
|
24
|
Magnúsdóttir V, Stefánsson E. [Choroidal haemangioma worsens after laser therapy for skin port-wine nevus and improves with photodynamic therapy in the eye]. LAEKNABLADID 2007; 93:119-21. [PMID: 17277408] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/13/2023] Open
Abstract
A young man with facial port-wine nevus on one side of his face underwent skin laser treatment on his facial lesions and experienced worsening visual acuity from 0.9 to 0.4 and metamorphosis afterwards in the ipsilateral eye. He was found to have a choroidal haemangioma with an exudative retinal detachment. He received photodynamic therapy resulting in resolution of subretinal fluid and shrinkage of the haemangioma. Visual acuity decreased to 0.1 one week following photodynamic treatment, but improved steadily after that. Nine months following the treatment the visual acuity is 0.5 and metamorphosis is absent.
Collapse
|
25
|
Höcht S, Wachtlin J, Bechrakis NE, Schäfer C, Heufelder J, Cordini D, Kluge H, Foerster M, Hinkelbein W. Proton or photon irradiation for hemangiomas of the choroid? A retrospective comparison. Int J Radiat Oncol Biol Phys 2006; 66:345-51. [PMID: 16887287 DOI: 10.1016/j.ijrobp.2006.04.051] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2006] [Accepted: 04/14/2006] [Indexed: 11/30/2022]
Abstract
PURPOSE The aim of this study was to compare, on a retrospective basis, the results of therapy in patients with uveal hemangioma treated with photon or proton irradiation at a single center. METHODS From 1993 to 2002 a total of 44 patients were treated. Until 1998 radiotherapy was given with 6 MV photons in standard fractionation of 2.0 Gy 5 times per week. In 1998 proton therapy became available and was used since then. A dose of 20 to 22.5 Cobalt Gray Equivalent (CGE) 68 MeV protons was given on 4 consecutive days. Progressive symptoms or deterioration of vision were the indications for therapy. RESULTS Of the 44 patients treated, 36 had circumscribed choroidal hemangiomas and 8 had diffuse choroidal hemangiomas (DCH) and Sturge-Weber syndrome. Of the patients, 19 were treated with photons with a total dose in the range of 16 to 30 Gy. A total of 25 patients were irradiated with protons. All patients with DCH but 1 were treated with photons. Stabilization of visual acuity was achieved in 93.2% of all patients. Tumor thickness decreased in 95.4% and retinal detachment resolved in 92.9%. Late effects, although generally mild or moderate, were frequently detected. In all, 40.9% showed radiation-induced optic neuropathy, maximum Grade I. Retinopathy was found in 29.5% of cases, but only 1 patient experienced more than Grade II severity. Retinopathy and radiation-induced optic neuropathy were reversible in some of the patients and in some resolved completely. No differences could be detected between patients with circumscribed choroidal hemangiomas treated with protons and photons. Treatment was less effective in DCH patients (75%). CONCLUSIONS Radiotherapy is effective in treating choroidal hemangiomas with respect to visual acuity and tumor thickness but a benefit of proton therapy could not be detected. Side effects are moderate but careful monitoring for side effects should be part of the follow-up procedures.
Collapse
Affiliation(s)
- Stefan Höcht
- Clinic for Radiation Oncology and Radiotherapy, Department for Ophthalmology, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany.
| | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Hasegawa A, Mizoe JE, Mizota A, Tsujii H. Outcomes of visual acuity in carbon ion radiotherapy: Analysis of dose–volume histograms and prognostic factors. Int J Radiat Oncol Biol Phys 2006; 64:396-401. [PMID: 16182466 DOI: 10.1016/j.ijrobp.2005.07.298] [Citation(s) in RCA: 56] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2005] [Revised: 07/08/2005] [Accepted: 07/08/2005] [Indexed: 11/21/2022]
Abstract
PURPOSE To analyze the tolerance dose for retention of visual acuity in patients with head-and-neck tumors treated with carbon ion radiotherapy. METHODS AND MATERIALS From June 1994 to March 2000, 163 patients with tumors in the head and neck or skull base region were treated with carbon ion radiotherapy. Analysis was performed on 54 optic nerves (ONs) corresponding to 30 patients whose ONs had been included in the irradiated volume. These patients showed no evidence of visual impairment due to other factors and had a follow-up period of >4 years. All patients had been informed of the possibility of visual impairment before treatment. We evaluated the dose-complication probability and the prognostic factors for the retention of visual acuity in carbon ion radiotherapy, using dose-volume histograms and multivariate analysis. RESULTS The median age of 30 patients (14 men, 16 women) was 57.2 years. Median prescribed total dose was 56.0 gray equivalents (GyE) at 3.0-4.0 GyE per fraction per day (range, 48-64 GyE; 16-18 fractions; 4-6 weeks). Of 54 ONs that were analyzed, 35 had been irradiated with <57 GyE (maximum dose [Dmax]) resulting in no visual loss. Conversely, 11 of the 19 ONs (58%) irradiated with >57 GyE (Dmax) suffered a decrease of visual acuity. In all of these cases, the ONs had been involved in the tumor before carbon ion radiotherapy. In the multivariate analysis, a dose of 20% of the volume of the ON (D20) was significantly associated with visual loss. CONCLUSIONS The occurrence of visual loss seems to be correlated with a delivery of >60 GyE to 20% of the volume of the ON.
Collapse
Affiliation(s)
- Azusa Hasegawa
- Hospital, Charged Particle Research Center, National Institute of Radiological Sciences, Chiba, Japan.
| | | | | | | |
Collapse
|
27
|
Szuścik I, Romanowska-Dixon B, Markiewicz A, Pogrzebielski A, Jakubowska B. [Radiation optic neuropathy after the brachytherapy of the uveal melanoma]. Klin Oczna 2006; 108:278-80. [PMID: 17290823] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/13/2023]
Abstract
PURPOSE The evaluate the frequency of radiation of the optic neuropathy (RON) and its influence on visual acuity in patients with choroidal melanoma treated by brachytherapy. MATERIAL AND METHODS We analyzed 583 patients with choroidal melanoma, treated with ruthenium (106Ru) or iodine (125I) plaques in Ophthalmology Department of Jagiellonian University, between 1996 and 2004 year. The frequency of RON, its influence on loss of vision, according to a kind of the used isotope, tumor size and location were analyzed. Diagnosis of RON was established on the base of characteristic symptoms in the eye fundus. RESULTS The frequency of RON was significantly higher in cases treated by 125I vs 106Ru (14% vs 8.2%, p = 0.0014), in cases of tumors located in the posterior pole (31.3%, p = 0.012), and in cases of tumor thickness 3-8 mm (27.5%, p = 0.033). In most of patients we observed major deterioration of visual acuity. CONCLUSIONS The radiation of the optic neuropathy was seen often after iodine BT, tumors located in the posterior pole of fundus, with thickness 3-8 mm.
Collapse
Affiliation(s)
- Iwona Szuścik
- Katedry i Kliniki Okulistyki, Collegium Medicum Uniwersytetu Jagiellońskiego w Krakowie
| | | | | | | | | |
Collapse
|
28
|
Kubicka-Trzaska A, Romanowska-Dixon B. [Choroidal metastases from breast cancer--clinical observations of 18 cases]. Klin Oczna 2006; 108:281-4. [PMID: 17290824] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/13/2023]
Abstract
PURPOSE To present clinical picture and results of treatment of breast carcinoma metastases to choroid. MATERIAL AND METHODS Eighteen females (26 eyes), age: 31-70 years old; mean age: 50.5 +/-14.5 years with breast carcinoma choroidal metastases were enrolled in this study. Choroidal metastases occurred 1 month to 288 months, mean: 64 +/- 33 months, after primary tumors had been diagnosed. In all cases basic eye examination with ultrasonography as well as fluorescein and indocyanine green angiography in some patients, were performed. Method of treatment was applied according to tumor size and its localization; 106Ru plaque therapy was used in 8 cases, I25I in 2, transpupillary therapy (TTT) in 8, 106Ru + TTT ("sandwich method") in 4, teleradiotherapy in 3 and enucleation was performed in one case. The follow-up period ranged from 6 months to 5 years, mean 15.3 +/- 7.7 months. RESULTS Unilateral choroidal metastases were present in 10 patients and bilateral in 8. Single metastatic lesions were detected in 15 patients and multiple in 3. Tumors thickness measured by ultrasonography ranged from 1.2 to 16.2 mm. After therapy regression of tumors was noted in 7 eyes (10 tumors), among which in four eyes (7 tumors) total regression was observed. Stabilization was found in 4 eyes (4 tumors) and progression in other 4 eyes (4 lesions). CONCLUSIONS Tumor size, its localization and general patient condition are the main factors deciding about the method in treatment of choroidal metastases. Plaque therapy and transpupillary thermotherapy are effective methods of treatment in majority of metastatic tumors. They induce tumor regression and in some cases they may provide improvement in visual acuity.
Collapse
|
29
|
van Ginderdeuren R, van Limbergen E, Spileers W. 18 years' experience with high dose rate strontium-90 brachytherapy of small to medium sized posterior uveal melanoma. Br J Ophthalmol 2005; 89:1306-10. [PMID: 16170122 PMCID: PMC1772893 DOI: 10.1136/bjo.2005.068460] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
AIM To analyse local tumour control, radiation related complications, visual acuity, enucleation rate, and survival after brachytherapy of small to medium sized choroidal melanoma (CM) with a high dose rate (HDR) strontium-90 (Sr-90) applicator. METHODS From 1983 until 2000, 98 eyes with CM were treated with Sr-90 brachytherapy. The main outcome measures were actuarial rates of the patients' survival, ocular conservation rate, tumour regression, complication rates, and preservation of visual acuity. End point rates were estimated using Kaplan-Meier analysis. RESULTS The median follow up time was 6.7 years (0.5-18.8 years). Actuarial melanoma free patient survival rate was 85% (SE 4.8%) after 18 years. Actuarial rate of ocular conservation and complete tumour regression was 90% (SE 3.8%) after 15 years. In 93% local tumour control was achieved, 88% showed a stable scar. Recurrence of the tumour on the border caused enucleation of six eyes (7%). In three cases (4%) retinal detachment was the end point. No cases of optic atrophy or of sight impairing retinopathy outside the treated area were found. Actuarial rate of preservation of visual acuity of 1/10 was 65% at 5 years and 45% at 15 years of follow up (SE 5.9% and 8.8%). CONCLUSIONS Sr-90 brachytherapy is as effective as iodine or ruthenium brachytherapy for small to medium sized CM but causes fewer complications. The preservation of vision is better than with all other described radioisotopes. HDR Sr-90 brachytherapy can therefore safely be recommended for small to medium sized CM.
Collapse
Affiliation(s)
- R van Ginderdeuren
- Department of Ophthalmology, Kapucijnenvoer 33, UZ Leuven, B3000 Leuven, Belgium.
| | | | | |
Collapse
|
30
|
Damato B, Patel I, Campbell IR, Mayles HM, Errington RD. Visual acuity after Ruthenium106 brachytherapy of choroidal melanomas. Int J Radiat Oncol Biol Phys 2005; 63:392-400. [PMID: 15990248 DOI: 10.1016/j.ijrobp.2005.02.059] [Citation(s) in RCA: 55] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2005] [Accepted: 02/01/2005] [Indexed: 11/18/2022]
Abstract
PURPOSE To report on conservation of visual acuity after Ruthenium(106) (Ru-106) brachytherapy of choroidal melanoma. METHODS AND MATERIALS This study was a noncomparative interventional case series of 458 patients with choroidal melanoma treated at a single center between January 1993 and December 2001. The intervention consisted of Ru-106 brachytherapy delivering minimum scleral and apex doses of 300 Gy and 80 Gy, respectively, using a 15-mm or 20-mm plaque. For discrete, posterior tumors, the plaque was positioned eccentrically with its posterior edge aligned with the posterior tumor margin. To ensure correct plaque positioning, any overlying extraocular muscles were dis-inserted, and the locations of both tumor and plaque edges were confirmed by transillumination and indentation. The main outcome measures were conservation of vision of 20/40 or better, 20/200 or better, and Counting Fingers or better, according to baseline variables. RESULTS The actuarial rate of conservation of 20/40 or better was 55% at 9 years, loss of such vision correlating with posterior tumor extension (p < 0.001), temporal tumor location (p = 0.001), increased tumor height (p = 0.01), and older age (p < 0.01) (Cox multivariate analysis). Similar analyses showed conservation of 20/200 or better in 57% of eyes at 9 years, loss correlating with reduced initial visual acuity (p < 0.001), posterior tumor extension (p < 0.001), and temporal tumor location (p = 0.006). Counting Fingers or better vision was conserved in 83% of patients at 9 years, loss correlating with increased tumor height (p < 0.0001). Local tumor recurrence occurred in 9 patients (actuarial rate, 3% at 9 years). CONCLUSION Ruthenium(106) brachytherapy of posterior choroidal melanoma achieves good conservation of vision if the tumor does not extend close to the optic nerve or fovea.
Collapse
Affiliation(s)
- Bertil Damato
- Ocular Oncology Service, St. Paul's Eye Unit, Royal Liverpool University Hospital, Prescot Street, Liverpool, United Kingdom.
| | | | | | | | | |
Collapse
|
31
|
Muller K, Nowak PJCM, de Pan C, Marijnissen JP, Paridaens DA, Levendag P, Luyten GPM. Effectiveness of fractionated stereotactic radiotherapy for uveal melanoma. Int J Radiat Oncol Biol Phys 2005; 63:116-22. [PMID: 16111579 DOI: 10.1016/j.ijrobp.2005.01.058] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2004] [Revised: 01/04/2005] [Accepted: 01/12/2005] [Indexed: 10/25/2022]
Abstract
PURPOSE To study the effectiveness and acute side effects of fractionated stereotactic radiation therapy (fSRT) for uveal melanoma. METHODS AND MATERIALS Between 1999 and 2003, 38 patients (21 male, 17 female) were included in a prospective, nonrandomized clinical trial (mean follow-up of 25 months). A total dose of 50 Gy was given in 5 consecutive days. A blinking light and a camera (to monitor the position of the diseased eye) were fixed to a noninvasive relocatable stereotactic frame. Primary end points were local control, best corrected visual acuity, and toxicity at 3, 6, 12, and 24 months, respectively. RESULTS After 3 months (38 patients), the local control was 100%; after 12 months (32 patients) and 24 months (15 patients), no recurrences were seen. The best corrected visual acuity declined from a mean of 0.21 at diagnosis to 0.06 2 years after therapy. The acute side effects after 3 months were as follows: conjunctival symptoms (10), loss of lashes or hair (6), visual symptoms (5), fatigue (5), dry eye (1), cataract (1), and pain (4). One eye was enucleated at 2 months after fSRT. CONCLUSIONS Preliminary results demonstrate that fSRT is an effective and safe treatment modality for uveal melanoma with an excellent local control and mild acute side effects. The follow-up should be prolonged to study both long-term local control and late toxicity.
Collapse
Affiliation(s)
- Karin Muller
- Department of Radiation Oncology, Erasmus Medical Center, Rotterdam, The Netherlands
| | | | | | | | | | | | | |
Collapse
|
32
|
Jensen AW, Petersen IA, Kline RW, Stafford SL, Schomberg PJ, Robertson DM. Radiation complications and tumor control after 125I plaque brachytherapy for ocular melanoma. Int J Radiat Oncol Biol Phys 2005; 63:101-8. [PMID: 16111577 DOI: 10.1016/j.ijrobp.2005.01.022] [Citation(s) in RCA: 57] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2004] [Revised: 01/04/2005] [Accepted: 01/11/2005] [Indexed: 11/17/2022]
Abstract
PURPOSE To determine the outcome of 125I plaque brachytherapy at our institution and identify the risk factors associated with the development of radiation complications, tumor recurrence, and metastasis. PATIENTS AND METHODS From 1986 to 2000, 156 patients underwent 125I episcleral plaque (COMS design) application for the treatment of ocular melanoma. Chart analysis of follow-up ophthalmologic appointments assessed the incidence of ocular side effects after therapy. Statistical analysis assessed outcomes and significant influencing factors. RESULTS With a median follow-up of 6.2 years, the 5-year overall survival was 83%. The 5-year disease-specific survival was 91%. Initial local control at 5 years was 92%, with 100% ultimate local control after secondary therapy that included 9 enucleations. The risk of metastasis was 10% at 5 years and 27% at 10 years. Vision stayed the same or improved in 25% of patients, and 44% of patients maintained visual acuity better than 20/200. Thirteen percent of patients experienced chronic pain or discomfort in the treated eye. Dose rates to the tumor apex greater than 90 to 100 cGy/h were associated with increased systemic control but worse radiation toxicity. CONCLUSION Patients in our series experienced excellent local tumor control. Higher dose rates to the tumor apex were associated with reduced rates of distant metastases but worse ocular function.
Collapse
Affiliation(s)
- Ashley W Jensen
- Department of Radiation Oncology, Mayo Medical School, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
| | | | | | | | | | | |
Collapse
|
33
|
Damato B, Kacperek A, Chopra M, Sheen MA, Campbell IR, Errington RD. Proton beam radiotherapy of iris melanoma. Int J Radiat Oncol Biol Phys 2005; 63:109-15. [PMID: 16111578 DOI: 10.1016/j.ijrobp.2005.01.050] [Citation(s) in RCA: 80] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2004] [Revised: 01/10/2005] [Accepted: 01/11/2005] [Indexed: 11/18/2022]
Abstract
PURPOSE To report on outcomes after proton beam radiotherapy of iris melanoma. METHODS AND MATERIALS Between 1993 and 2004, 88 patients with iris melanoma received proton beam radiotherapy, with 53.1 Gy in 4 fractions. RESULTS The patients had a mean age of 52 years and a median follow-up of 2.7 years. The tumors had a median diameter of 4.3 mm, involving more than 2 clock hours of iris in 32% of patients and more than 2 hours of angle in 27%. The ciliary body was involved in 20%. Cataract was present in 13 patients before treatment and subsequently developed in another 18. Cataract had a 4-year rate of 63% and by Cox analysis was related to age (p = 0.05), initial visual loss (p < 0.0001), iris involvement (p < 0.0001), and tumor thickness (p < 0.0001). Glaucoma was present before treatment in 13 patients and developed after treatment in another 3. Three eyes were enucleated, all because of recurrence, which had an actuarial 4-year rate of 3.3% (95% CI 0-8.0%). CONCLUSIONS Proton beam radiotherapy of iris melanoma is well tolerated, the main problems being radiation-cataract, which was treatable, and preexisting glaucoma, which in several patients was difficult to control.
Collapse
Affiliation(s)
- Bertil Damato
- St. Paul's Eye Unit, Royal Liverpool University Hospital, Liverpool, UK.
| | | | | | | | | | | |
Collapse
|
34
|
Hori K, Saito S, Tamai M. Effect of irradiation on neovascularization in rat skinfold chambers: implications for clinical trials of low-dose radiotherapy for wet-type age-related macular degeneration. Int J Radiat Oncol Biol Phys 2005; 60:1564-71. [PMID: 15590188 DOI: 10.1016/j.ijrobp.2004.06.208] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2004] [Revised: 06/21/2004] [Accepted: 06/28/2004] [Indexed: 11/19/2022]
Abstract
PURPOSE Wet-type age-related macular degeneration is a refractory eye disease that involves choroidal neovascularization. Randomized controlled trials of low-dose radiotherapy for this disease performed in Japan showed that, at 12 months of follow-up, visual acuity was significantly well preserved and the neovascular membrane size decreased. Because understanding the effect of irradiation on new vascular networks is an important prerequisite for clinical trials, we used a rat skinfold chamber technique to investigate X-ray-induced changes in neovasculature microcirculation. METHODS AND MATERIALS Neovascularization was induced in rat skinfold chambers via polyvinyl chloride resin plates. Neovessels were irradiated in a single 10-Gy dose, after which, changes in vascular density, blood velocity, tissue blood flow, and interstitial fluid pressure (IFP), were measured. RESULTS Vascular density, tissue blood flow, and IFP measurements in resin-induced inflammatory tissue were much higher than those measurements in normal tissue. Although overall blood velocity was low and sluggish or blood-flow stasis occurred in the neovascular network, after a single 10-Gy dose of radiation, the velocity increased, stasis improved markedly, and many dilated vessels narrowed. Thereafter, vascular density, blood flow, and IFP significantly decreased and approached normal values. CONCLUSION These findings may help explain clinical results related to radiotherapy-induced changes in neovascular membranes in age-related macular degeneration. Both vascular morphology and vascular function in inflammatory tissue returned to normal, without vessel destruction, after an appropriate radiation dose.
Collapse
Affiliation(s)
- Katsuyoshi Hori
- Department of Vascular Biology, Division of Cancer Control, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan.
| | | | | |
Collapse
|
35
|
Churei H, Ohkubo K, Nakajo M, Hokotate H, Baba Y, Ideue J, Miyagawa K, Nakayama H, Hiraki Y, Kitasato T, Yabe N. External-beam radiation therapy for age-related macular degeneration: two years' follow-up results at a total dose of 20 Gy in 10 fractions. Radiat Med 2004; 22:398-404. [PMID: 15648455] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/01/2023]
Abstract
PURPOSE The efficacy of external-beam radiation therapy (RT) was evaluated in the treatment of eyes with subfoveal or juxtafoveal choroidal neovascularization in age-related macular degeneration (ARMD). MATERIALS AND METHODS Twenty-one eyes of 18 patients with occult or mixed-type ARMD received a total dose of 20 Gy of 6 MV X-rays in 10 fractions. The follow-up time was 24 months. Fifteen non-treated eyes of 13 patients who had been followed served as a control. RESULTS In the RT group, visual acuity was improved in three eyes, maintained in 14 eyes, and worsened in four eyes. In the control group, it was not improved in any eyes, was maintained in six eyes, and worsened in nine eyes. The improved or maintained rate in visual acuity was 81% in the RT group and 40% in the control group (p=0.0342). In the RT group, fundoscopic and angiographic findings were improved in five eyes, unchanged in seven eyes, and worsened in nine eyes, while they were not improved in any eyes, unchanged in two eyes, and worsened in 13 eyes in the control group(p=0.0342). CONCLUSION RT at a total dose of 20 Gy in 10 fractions is effective for ARMD for at least two years. RT may be effective treatment for occult or mixed-type ARMD compared with the classic type.
Collapse
Affiliation(s)
- Hisahiko Churei
- Department of Radiology, Kagoshima University Hospital, Kagoshima University Hospital, Sakuragaoka, Kagoshimashi, Kagoshima, Japan
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Abstract
PURPOSE Large uveal melanomas located close to the optic nerve and/ or to the fovea have an unfavourable prognosis with regard to visual preservation and eye retention, due to the high incidence of radiation and tumour necrosis induced complications. Endoresection of the tumour after proton beam irradiation, is an alternative approach, aiming to reduce the incidence of ocular morbidity caused by tumour necrosis after sole radiotherapy. PATIENTS AND METHODS 32 patients with large uveal melanomas (mean tumour thickness: 9.1 mm, mean tumour volume: 0.77 cc), received a primary proton beam irradiation (60 CGE) and underwent subsequent endoresection via a 3-port pars plana vitrectomy. The median pretreatment visual acuity was 0.2. The mean follow-up was 13.9 months. RESULTS The postoperative visual acuity after 12 months was 0.12 (median, mean visual acuity loss 0.08). The probability of developing radiation retinopathy or papillopathy within the first year after treatment was 35% and 28% respectively and the probability of enucleation was 9% within the first postoperative year. No tumour recurrences were observed and 2 patients developed liver metastases. CONCLUSIONS Endoresection following irradiation of large uveal melanomas located close to the optic nerve and/ or the fovea seems to be a useful and safe alternative to the traditional irradiation or enucleation. The incidence of complications following our approach seems to be lower when compared to radiation alone, where tumour necrosis is a substantial problem.
Collapse
Affiliation(s)
- N E Bechrakis
- Augenklinik, Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin.
| | | | | | | | | | | |
Collapse
|
37
|
Esassolak M, Karagöz U, Yalman D, Köse S, Anacak Y, Haydaroğlu A. Evaluation of the effects of radiotherapy to the chiasm and optic nerve by visual psychophysical and electrophysiologic tests in nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2004; 58:1141-6. [PMID: 15001256 DOI: 10.1016/j.ijrobp.2003.08.014] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2003] [Revised: 07/14/2003] [Accepted: 08/11/2003] [Indexed: 11/19/2022]
Abstract
PURPOSE To evaluate the effects of high-dose radiotherapy (RT) to the chiasm and optic nerves in locally advanced nasopharyngeal carcinoma patients by visual psychophysical and electrophysiologic tests. METHODS AND MATERIALS A series of visual tests, including visual evoked potentials (VEPs), contrast sensitivity, and visual field and visual acuity tests, were administered to 27 patients with locally advanced (T4) nasopharyngeal carcinoma who had undergone RT to high doses 6 to 74 months previously. As a control group, the same tests were administered to 40 unirradiated patients who had been referred to the ophthalmology department for any reason. RESULTS The median values of VEP latency, VEP amplitude, and contrast sensitivity and the rate of visual field defect were significantly worse in the RT group (p = 0.06, p <0.001, p <0.001, and p = 0.005, respectively). No dose-response relationship was found in any tests when 50 Gy was the cutoff value. However, a positive correlation between the interval after RT and VEP latency (r = 0.406, p = 0.003) and a negative correlation between the interval and contrast sensitivity (r = -0.499, p <0.001) was noted; no correlation could be established regarding VEP amplitude and the interval after RT. CONCLUSION Radiation-induced injury to the anterior visual pathways could result in an increase in VEP latency and a decrease in VEP amplitude and contrast sensitivity. This injury seems to be a continuous process developing with time.
Collapse
Affiliation(s)
- Mustafa Esassolak
- Department of Radiation Oncology, Ege University Faculty of Medicine, Izmir, Turkey.
| | | | | | | | | | | |
Collapse
|
38
|
Prettenhofer U, Haas A, Mayer R, Stranzl H, Oechs A, Hackl A. Long-term results after external radiotherapy in age-related macular degeneration. A prospective study. Strahlenther Onkol 2004; 180:91-5. [PMID: 14762661 DOI: 10.1007/s00066-004-1177-6] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2003] [Accepted: 09/29/2003] [Indexed: 12/01/2022]
Abstract
PURPOSE To prospectively evaluate the short- and long-term efficacy of external radiotherapy (RT) in patients with age-related macular degeneration (AMD) by comparing two different dose schedules. PATIENTS AND METHODS In this prospective, nonrandomized, comparative study including 80 patients, the efficacy of external RT with a total dose of 14.4 Gy (group A, n = 40) and 25.2 Gy (group B, n = 40) was compared. Patients of group A were irradiated between September 1995 and July 1996, patients of group B between August 1996 and November 1997. 67 patients presented with occult choroidal neovascularization (CNV), 13 with classic subfoveal lesions. Complete ophthalmologic investigation was performed before RT, at intervals of 3 months during the 1st year after RT, and of 6 months thereafter. RESULTS 12 months after RT, vision deteriorated in 85% (14.4 Gy) and 65% (25.2 Gy) of patients. Central visual field decreased with both dose schedules. There was no morphological benefit in neovascular changes. After 48 months, complete follow-up was possible in 46 patients who showed a significant loss of vision similar to the natural course of AMD. CONCLUSION External RT of AMD with 14.4 Gy as well as with the escalated dose of 25.2 Gy showed a poor beneficial outcome after 6 and 12 months, respectively. After a follow-up of 4 years, visual outcome in irradiated patients was similar to the natural course of the disease. A conspicuous efficacy of RT in prevention of blindness could not be demonstrated.
Collapse
|
39
|
|
40
|
Nishiguchi KM, Sandberg MA, Kooijman AC, Martemyanov KA, Pott JWR, Hagstrom SA, Arshavsky VY, Berson EL, Dryja TP. Defects in RGS9 or its anchor protein R9AP in patients with slow photoreceptor deactivation. Nature 2004; 427:75-8. [PMID: 14702087 DOI: 10.1038/nature02170] [Citation(s) in RCA: 125] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2003] [Accepted: 10/14/2003] [Indexed: 11/09/2022]
Abstract
The RGS proteins are GTPase activating proteins that accelerate the deactivation of G proteins in a variety of signalling pathways in eukaryotes. RGS9 deactivates the G proteins (transducins) in the rod and cone phototransduction cascades. It is anchored to photoreceptor membranes by the transmembrane protein R9AP (RGS9 anchor protein), which enhances RGS9 activity up to 70-fold. If RGS9 is absent or unable to interact with R9AP, there is a substantial delay in the recovery from light responses in mice. We identified five unrelated patients with recessive mutations in the genes encoding either RGS9 or R9AP who reported difficulty adapting to sudden changes in luminance levels mediated by cones. Standard visual acuity was normal to moderately subnormal, but the ability to see moving objects, especially with low-contrast, was severely reduced despite full visual fields; we have termed this condition bradyopsia. To our knowledge, these patients represent the first identified humans with a phenotype associated with reduced RGS activity in any organ.
Collapse
Affiliation(s)
- Koji M Nishiguchi
- Ocular Molecular Genetics Institute, Harvard Medical School, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts 02114, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Nepp J, Dorner GT, Jandrasits K, Maar N, Schild G, Wedrich A. Ocular surface changes and tear film alterations associated with sun gazing during a solar eclipse. Wien Klin Wochenschr 2003; 115:47-52. [PMID: 12658911 DOI: 10.1007/bf03040272] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
PURPOSE A solar eclipse occurred in central Europe on August 11th, 1999. Following the eclipse, patients with ocular symptoms were investigated. Gazing at the sun without protection is liable to damage the retina. Our attention was focused on changes of the ocular surface and the tear film. METHODS Forty-three patients were investigated within one week after the solar eclipse as baseline. 33 of them were followed up one year later. Visual acuity and the central visual-field were measured, and the ocular surface and the fundus were examined using a slit lamp. The quality of the lacrimal tear film was examined using Schirmer's test for the aqueous layer, break-up time for the mucous layer and interference observation for the lipid layer, measured by a slit lamp and a tearoscope. RESULTS At the baseline 19 patients had non-specific visual problems. Pathological alterations of the tear film were seen in all three tear-film layers: Schirmer's test was pathological in 87%, break-up time decreased in 85%, the interference pattern of the lipid layer changed in 67% and there were changes in 87% using the tearoscope. One year later the non specific visual disorders had disappeared. Schirmer's test did not reveal much change from the baseline: 51% pathological, 24% remained pathological in break-up-time and the lipid layer was normalized except in 9%. Using the tearoscope, lipids were better than grade 3 in all patients. CONCLUSION After gazing at a solar eclipse the ocular surface and tear film changed. While the aqueous layer remained pathological in many patients, the lipid layer and the mucous layer recovered spontaneously.
Collapse
Affiliation(s)
- Johannes Nepp
- Department of Ophthalmology, University of Vienna, Medical School, Vienna, Austria.
| | | | | | | | | | | |
Collapse
|
42
|
Pitz S, Kahaly G, Rösler HP, Krummenauer F, Wagner B, Stübler M, Pfeiffer N. [Retrobulbar irradiation for Graves' ophthalmopathy -- long-term results]. Klin Monbl Augenheilkd 2002; 219:876-82. [PMID: 12548473 DOI: 10.1055/s-2002-36948] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
BACKGROUND Significance of retrobulbar irradiation in patients suffering form Graves' ophthalmopathy, though established since almost one century, is subject of scientific debate. The present study investigated the effect of retrobulbar irradiation using a standardized protocol focussing on long term results. PATIENTS AND METHODS Between 1981 and 1997, 104 patients treated by retrobulbar irradiation (10 to 20 Gray) due to Graves' disease. Twenty-nine of these underwent irradiation as sole treatment (mean follow-up 57 months), while in the remaining 75, it was combined with a systemic steroid treatment (mean follow-up 40 months). Patients were evaluated regarding proptosis, intraocular pressure, lid signs, motility as well as subjective assessment of double vision and retrobulbar pain. RESULTS While proptosis remained unchanged, lid signs, chemosis and intraocular pressure showed slight and statistically significant improvement. However, these findings were considered to be clinically insignificant. Retrobulbar pain was improved in 75 % of patients. 25 % of patients showed improved motility, 75 % remained stable, and in none of them was there a deterioration of ductions. Results proved stable even in long-term follow-up. 25 % per cent of patients underwent a surgical procedure one year after radiotherapy. CONCLUSIONS In our series, we could not demonstrate an additional benefit of systemic steroids when combined with retrobulbar irradiation. Up to sixteen years after treatment, no treatment-related adverse reaction was seen. We found a remarkable improvement in ocular motility. This holds even more true in comparison to the natural course of the condition. Retrobulbar irradiation seems to shorten the duration of the disease, thus allowing earlier performance of eventual rehabilitative surgery.
Collapse
Affiliation(s)
- Susanne Pitz
- Augenklinik, Johannes Gutenberg-Universität, Mainz
| | | | | | | | | | | | | |
Collapse
|
43
|
Abstract
Retinas of primates (Macaca mulatta) were exposed to oxygen nuclei at the Bevatron, Berkeley, California. Color fundus photographs and fluorescein angiograms were taken of the retinas prior to irradiation and up to 5 weeks post exposure. Animals were sacrificed at post exposure intervals for histopathologic examination of the retinas. A series of animals were exposed to 200 kVp X-ray and examined on the same regime as the first series. The results showed a low rad equivalent dose for retinal damage as compared with the X-ray series, i.e., a high quality factor, and a marked compression of the latency between exposure and onset of the retinal pathology.
Collapse
Affiliation(s)
- C H Bonney
- USAF School of Aerospace Medicine, Brooks Air Force Base, Texas, USA
| | | | | |
Collapse
|
44
|
Stoffelns BM, Kutzner J, Jochem T. [Retrospective analysis of ruthenium-106 brachytherapy for small and medium-sized malignant melanoma of the posterior choroid]. Klin Monbl Augenheilkd 2002; 219:216-20. [PMID: 12022004 DOI: 10.1055/s-2002-30654] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
BACKGROUND Transpupillary thermotherapy is a new and most promising treatment modality for up to medium-sized choroidal melanoma at the posterior pole. We analysed the results of conventional ruthenium-106 brachytherapy in these special tumour subgroup. PATIENTS AND METHODS Results of ruthenium-106 brachytherapy (radioactive dose to the tumour apex 150 Gy) in a series of 52 eyes with primary malignant choroidal melanoma (posterior to the equator, thickness </= 4.5 mm, base diameter </= 12 mm) were evaluated retrospectively. Mean tumour thickness was 3.2 mm. The posterior tumour margin was in 20 eyes </= 2 optic disc diameter away from the macula and in 10 eyes </= 2 optic disc diameter away from the optic disc. Follow-up was 3 - 9 years (median 5.6 years). RESULTS Tumour control was achieved in 48 eyes (92 %): completely flattened scar in 71 %, residual prominence </= 2 mm in 16 %, no apparent response (but high reflectivity in ultrasonographic examination) in 5 %. 4 eyes were removed because of tumour regrowth (3 x) or secondary glaucoma (1 x). Visual outcome mainly depends on tumour location in respect of fovea and the optic nerve. Because 40 % of the eyes developed radiation maculopathy and 20 % radiation optic neuropathy 25 eyes (48 %) reached a final visual acuity </= 0.2. 40 eyes (77 %) revealed a visual loss of at least 2 lines. Two patients died of liver metastases. CONCLUSION In posterior choroidal melanoma ruthenium-brachytherapy achieved an excellent rate of tumour control, but functional results were disappointing because of late radiation sideeffects. Transpupillary thermotherapy as an adjunct to ruthenium plaque radiotherapy may be able to reduce the radioactive dose.
Collapse
|
45
|
Caminal Mitjana JM, Quintana Casany M, Pera Fábregas J, Cinos Cope C, Guedea F. [Results of Iodine-125 radiotherapy in the treatment of uveal melanoma]. Arch Soc Esp Oftalmol 2002; 77:29-38. [PMID: 11813118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
Abstract
PURPOSE To evaluate our experience in the treatment of uveal melanoma by means of Iodine-125 brachytherapy. A reprospective case series study. MATERIAL AND METHOD Patients diagnosed of uveal melanoma and treated with Iodine-125 brachytherapy in the Ciudad Sanitaria y Universitaria de Bellvitge (CDUV), from September 1996 to December 2000 and follow up of more than one year. RESULTS During the period of study, 145 patients were diagnosed of uveal melanoma, of which, 77 were treated with Iodine-125 COMS type plaques; among these, 58 were elegible for this study. After a mean of 2.4 year follow up period (878 days) a mean reduction in height of 53.84% and a mean reduction in volume of 75.88% was observed. As for visual acuity, 32.7% of patients presented a vision of 0.1 or better in last follow up check; 13.5% presented low vision at the moment of diagnosis and continued the same up to last follow up check. The rest of patients experienced loss which conditioned vision to less than 0.1. As for complications, we have observed transient diplopia (8.6%), cataract (3.4%), vitreous bleeding (10.3%), neovascular glaucoma (6.8%), radiation retinopathy (17.24%), radiation neuropathy (6.8%), posterior scleritis (2%), pigmental scattering (2%), tumor progression (2%), endophtalmitis (2). Secondary enucleations were carried out in 6.8% of patients. Metastatic disease was observed in 15.5% of the patients. CONCLUSIONS Brachytherapy with Iodine-125 may induce significant regression in most of patients affected of uveal melanoma, with good preservation of visual acuity and a low rate of complications.
Collapse
Affiliation(s)
- J M Caminal Mitjana
- Ciutat Sanitaria i Universitaria de Bellvitge, L'Hospitalet, Barcelona, España
| | | | | | | | | |
Collapse
|
46
|
Schittkowski M, Schneider H, Grüschow K, Ziegler PG, Guthoff R, Fietkau R. [3 years experience with low dosage fractionated percutaneous teletherapy in subfoveal neovascularization. Clinical results]. Strahlenther Onkol 2001; 177:345-53. [PMID: 11505620 DOI: 10.1007/pl00002417] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
AIM The effect of low dose fractionated percutaneous teletherapy to visual acuity and the changes in subfoveolar neovascular membranes in age-related macular degeneration were investigated. PATIENTS AND METHOD 126 eyes of 118 patients (age 55-89 years; mean 74 ys.) were treated. Best distal and near visual acuity was assessed prior to (= initial visual acuity [IVA]) and 3, 6, 12, 18, 24, 30 and 36 months after teletherapy. Fluorescein angiography was performed prior to and 6, 12, 24 and 36 months after radiation therapy. For analysis patients were divided into different groups by IVA and membrane size. Maximal duration of observation was 36 months. Teletherapy was done by a 9-MeV photon linear accelerator through a lateral port in half-beam technique with a single dose of 2 Gy up to a total dose of 20 Gy within 12 days. RESULTS No severe negative side effects have been observed. Eight patients reported of epiphora and four patients complained of transient sicca syndrome. Visual acuity decreased more than one line in the group IVA 0.05-0.2. The group IVA 0.3-0.5 remained unchanged for 1 year. We found a tendency for increased visual acuity in group IVA > or = 0.6 for 18 months. After that time both groups showed decreased visual acuity, but all these patients reported of reduced metamorphopsia and increased color and contrast perception. CONCLUSIONS There is an influence of low dose fractionated percutaneous teletherapy on visual acuity, subfoveal neovascular membranes and metamorphopsia. IVA and duration of anamnesis play an important role. There seems to be no persistent effect; possibly increased dosage will bring a benefit.
Collapse
|
47
|
Abstract
AIM To examine how tumour location affects ocular morbidity after ophthalmic plaque radiotherapy for uveal melanoma. METHODS 69 eyes were irradiated and followed for a mean 42 months. There were 23 anterior uveal melanomas and 46 were posterior to the equator. Anterior and posterior tumours had similar basal dimensions. Their mean apical heights were 4.8 mm (anterior) and 3.5 mm (posterior) which received a mean 88 Gy and 83.4 Gy respectively. RESULTS Only one patient (4%) plaqued for an anterior uveal melanoma developed secondary retinopathy (cystoid macular oedema). In contrast, 24 (52%) of the posterior choroidal melanoma patients developed retinopathy (p value <0.0001). Cataract developed in 18 (86%) eyes with phakic anterior tumour compared with seven (17%) eyes with posterior tumours (p value <0.0000). No posterior nasal tumours lost more than two lines of vision though 45% developed retinopathy. CONCLUSION While plaque radiation of anterior melanomas is more likely to cause reversible vision loss secondary to cataract, treatment of posterior tumours is more likely to be associated with irreversible loss because of retinopathy. Nasal location is also protective against severe loss of vision.
Collapse
Affiliation(s)
- P T Finger
- New York Eye Cancer Centre, New York Eye and Ear Infirmary, and Department of Ophthalmology, New York University School of Medicine, New York City 10021, USA.
| |
Collapse
|
48
|
Mohamed IG, Roa W, Fulton D, Halls S, Jha N, Kherani A, Johnson R. Optic nerve sheath fenestration for a reversible optic neuropathy in radiation oncology. Am J Clin Oncol 2000; 23:401-5. [PMID: 10955872 DOI: 10.1097/00000421-200008000-00018] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
To the authors' knowledge, there is a paucity of published accounts of management of radiation-induced optic neuropathy (RION) by optic nerve sheath fenestration (ONSF) in the conventional medical literature. With higher doses of radiation being given by using conformal techniques, more radiation-induced optic neuritis and neuropathy will be identified. We report here the successful use of ONSF to restore vision to three consecutive patients with pending anterior RION, and the importance of early identification and intervention in these potentially reversible cases.
Collapse
Affiliation(s)
- I G Mohamed
- Department of Oncology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada
| | | | | | | | | | | | | |
Collapse
|
49
|
Abstract
BACKGROUND/AIM Limited treatments are available for this disease process. A pilot study was performed to determine the toxicity and efficacy of external beam radiotherapy for subfoveal neovascular membranes and subretinal haemorrhage associated with pathological myopia. METHODS A randomised, prospective study was carried out on 39 patients with subfoveal neovascularisation associated with high myopia. 20 patients underwent radiotherapy and the remaining 19 were observed as a randomised comparison group. All patients were followed up for at least 24 months. Subfoveal choroidal neovascular membranes (CNVMs) were treated with a single lateral 6 MV photon beam to a dose of 10 Gy in five fractions over 5-7 days. Post-treatment measurements included corrected visual acuity, area of CNVM, and occurrence of radiotherapy related complications, and adverse reactions. To assess changes of area of CNVM, the initial (pretreatment) size of the CNVM was set to 100%, and all post-treatment measurements were normalised relative to the initial size. RESULTS No significant acute morbidity was noted. There was no significant difference in age, sex, refractive error, visual acuity, and area of CNVM at baseline between the treatment group and control group. The mean change of the size of the CNVM for 2 years was 155% (SD 156%) in the treatment group and 249% (124%) in the control group. The increase in the size of CNVM in the treatment group was significantly smaller than that in the control group (p = 0.0452). In the treated eyes, the visual acuity before and 1 and 2 years after radiotherapy were 0.111 (22.2/200), 0.091 (18.2/200), and 0.086 (19.2/200), respectively. In the control eyes, visual acuity before and 1 and 2 years after the start of the follow up were 0.141 (34.2/200), 0.089 (17.8/200), and 0.063 (12.6/200). The patients in the treatment group showed no significant change for 2 years, and those in the control group showed a significant decrease in the visual acuity (p = 0.0033). The changes of logMAR of visual acuity for 2 years after the start of the follow up were +0.019 (0. 443) in the treatment group and +0.347 (0.374) in the control group. There was a statistically significant difference between them (p = 0. 0173). Multiple regression analysis on the treatment group showed that the most significant predictive variable for the visual acuity 2 years after the treatment was the combination of pretreatment visual acuity and refractive error. CONCLUSIONS Radiotherapy appeared to have a favourable treatment effect in eyes with subfoveal neovascular membranes and haemorrhage associated with pathological myopia. Further investigation is needed to evaluate the efficacy of radiotherapy for subfoveal neovascularisation associated with pathological myopia.
Collapse
Affiliation(s)
- H Kobayashi
- Department of Ophthalmology, Amagasaki Hospital, Hyogo, Japan.
| | | |
Collapse
|
50
|
Gragoudas ES, Lane AM, Regan S, Li W, Judge HE, Munzenrider JE, Seddon JM, Egan KM. A randomized controlled trial of varying radiation doses in the treatment of choroidal melanoma. Arch Ophthalmol 2000; 118:773-8. [PMID: 10865313 DOI: 10.1001/archopht.118.6.773] [Citation(s) in RCA: 126] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
OBJECTIVE To determine if a reduction in proton radiation dose from the standard dose of 70 cobalt gray equivalents (CGE) to 50 CGE would decrease radiation-induced complications, thereby improving visual prognosis, without compromising local tumor control for patients with uveal melanoma at high risk of these complications. DESIGN Randomized, double-masked clinical trial. PARTICIPANTS A total of 188 patients with small or medium-sized choroidal melanomas (<15 mm in diameter and <5 mm in height) near the optic disc or macula (within 4 disc diameters of either structure). METHODS Patients were treated with proton beam therapy at doses of either 50 CGE or 70 CGE between October 1989 and July 1994, and followed up biannually through April 1998. Outcomes included visual acuity, radiation complications, melanoma recurrence, and metastasis. RESULTS Proportions of patients retaining visual acuity of at least 20/200 were similar in the 2 dose groups at 5 years after radiation (approximately 55%). Similar numbers of patients in each group experienced tumor regrowth (2 patients at 50 CGE vs 3 patients at 70 CGE; P>.99) and metastasis (7 patients at 50 CGE vs 8 patients at 70 CGE;P=.79). Five-year rates of radiation maculopathy also were similar (for both groups, approximately 75% for tumors within 1 disc diameter and 40% for tumors >1 disc diameter from the macula). Rates of radiation papillopathy were nonsignificantly decreased in the 50-CGE treatment group when tumors were located 1 disc diameter or less from the optic disc (P=.20). Patients treated with the lower dose also experienced significantly less visual field loss. CONCLUSIONS This level of dose reduction did not result in a lesser degree of visual acuity loss. The lower-dose group did experience significantly less visual field loss. Local tumor recurrence and metastatic death rates were similar in both dose groups. Arch Ophthalmol. 2000;118:773-778
Collapse
Affiliation(s)
- E S Gragoudas
- Retina Service, Massachusetts Eye and Ear Infirmary, 243 Charles St, Boston, MA 02114, USA
| | | | | | | | | | | | | | | |
Collapse
|